iPhot receives a 940K€ grant

Article

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

“The ultimate goal of the iPhot project is to optimize the process of adaptive-optics enabled retinal imaging in order to obtain morphological, quantitative and longitudinal information at the level of single photoreceptor cells in humans” notes Imagine Eyes' CEO Nicolas Chateau. Adding: “Clinical investigations related to this particular project will be focused on early detection of photoreceptor damage in cases of genetically or phenotypically defined inheritable retinal dystrophies. As the project and its technology advances, we plan to partner with additional clinical investigation sites to perform research on the healthy retina as well as other retinal diseases.”

“Unfortunately, most cases retinal of disease are diagnosed only once the patient has suffered significant, irreparable vision loss” says Pr. Michel Paques, iPhot's Project Coordinator, from the Quinze-Vingts hospital. “Functional testing detects visual impairment only once a significant proportion of cells have degenerated. More importantly, functional defects, and the associated morphological changes at the level of outer segments, can precede cell loss. The current imaging technologies that are used to diagnose and monitor the effectiveness of treatment lack the cellular level resolution needed to observe the retinal microstructures causing the visual dysfunction. The comprehensive analysis of the relationship between structural and functional parameters will guide both prognostic assessment and therapeutic decision making in affected patients. It should equally provide clues to discriminate and quantify irreversible versus reversible lesions.”

To view images obtained with Imagine Eyes' adaptive-optics retinal camera, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.